A clinical research organization, commonly called a CRO, is a company that pharmaceutical and biotech firms hire to manage some or all of the work involved in testing new drugs, vaccines, and medical devices. Rather than running every clinical trial in-house, drug developers outsource tasks like study design, patient recruitment, data collection, and regulatory paperwork to these specialized firms. About half of all clinical trial activities at pharmaceutical companies are now outsourced to CROs, making them a central part of how new treatments reach the market.
What a CRO Actually Does
At its core, a CRO exists to move a potential treatment from laboratory testing through human trials and toward regulatory approval. The range of work is broad. A single trial might require designing the study protocol, selecting the hospitals and clinics where patients will be enrolled, building databases to track results, monitoring patient safety throughout the study, running statistical analyses on the outcomes, and preparing the massive submission packages that agencies like the FDA require before approving a new drug.
A typical CRO’s service list includes:
- Protocol development: Writing the detailed plan that defines how a trial will be conducted, who qualifies to participate, and what outcomes will be measured.
- Site selection and startup: Identifying which hospitals, clinics, or research centers are best positioned to recruit the right patients and run the trial effectively.
- Clinical project management: Coordinating timelines, budgets, and communication across dozens or sometimes hundreds of trial sites in multiple countries.
- Study monitoring: Sending trained monitors to trial sites (or reviewing data remotely) to verify that the study is being conducted properly and that patient safety protocols are followed.
- Data management and biostatistics: Collecting, cleaning, and analyzing trial data, then translating those results into the statistical evidence regulators need to evaluate a drug’s safety and effectiveness.
- Regulatory affairs: Preparing and filing applications with regulatory agencies worldwide, navigating different requirements across countries and regions.
- Safety oversight: Tracking adverse events during the trial and reporting them to the appropriate authorities.
Some CROs also handle the supporting paperwork for drug approval submissions, which can run tens of thousands of pages and must meet strict formatting and content standards set by each regulatory body.
Full-Service vs. Specialty CROs
Not all CROs do the same thing. The industry splits roughly into two categories: full-service organizations that handle a trial from start to finish, and specialty CROs that focus on a narrow slice of the process.
Full-service CROs provide end-to-end support, covering project management, site selection, data management, biostatistics, clinical monitoring, regulatory affairs, and safety reporting under one contract. This model works well for companies that want a single partner coordinating everything, particularly when launching multiple trials in quick succession. A streamlined contract with one provider can mean faster startup and simpler logistics compared to juggling several vendors.
Specialty CROs, by contrast, concentrate on a specific therapeutic area (like oncology or rare diseases), a particular service (like data management alone), a specific development phase, or a geographic region. These firms tend to be more flexible and can offer deeper expertise in their niche. If a trial involves an unusual design, such as an adaptive study where the protocol changes based on interim results, a specialty biometrics firm with direct experience in that approach may navigate mid-study pivots more effectively than a generalist provider. Companies with a robust pipeline in a single disease area often benefit from working with a CRO that specializes in that therapeutic space and understands the specific regulatory challenges involved.
Why Drug Companies Use CROs
Running a clinical trial is expensive, complex, and requires highly specialized staff. A single late-stage trial can involve thousands of patients across dozens of countries, take several years, and cost hundreds of millions of dollars. Building and maintaining the internal infrastructure to do all of that is impractical for many companies, especially small biotech firms that may have only one or two drugs in development.
Outsourcing to a CRO gives a drug developer continuous access to experienced clinical service providers without the overhead of keeping that expertise on permanent payroll. The practical benefits include shorter development timelines, lower administrative costs, consistent processes and quality standards, and access to a larger pool of trained staff who can scale up quickly when a new trial launches. For a biotech startup with a promising molecule but no clinical operations team, a CRO can essentially serve as that entire department.
Even large pharmaceutical companies with their own clinical teams use CROs to supplement capacity during busy periods or to tap into regional expertise when running trials in countries where they have no established presence.
The Size of the CRO Industry
The CRO market has grown into a major global industry. It is projected to reach nearly $63 billion by 2030, growing at an average annual rate of about 7.4% from 2025 onward. North America remains the dominant region, though Asia-Pacific is growing rapidly. In 2024, North America held about 46% of the global CRO market share.
The industry is led by a handful of very large players. IQVIA, headquartered in Durham, North Carolina, is the world’s largest CRO with $15.4 billion in revenue in 2024. ICON, an Irish company, reported $8.28 billion. Syneos Health, before going private in 2023, had revenue of roughly $5.4 billion. Parexel brings in an estimated $3.8 billion, and Medpace, a mid-sized CRO based in Cincinnati, reported $2.1 billion in 2024 revenue with nearly 12% year-over-year growth. Thermo Fisher Scientific also operates a major CRO division through its 2021 acquisition of PPD for $17.4 billion.
Below these large organizations sits a long tail of smaller, often highly specialized firms serving particular therapeutic areas, regions, or development phases.
How CROs Fit Into Drug Development
A new drug typically moves through preclinical testing (in labs and animal models), then through three phases of human trials before it can be submitted for regulatory approval. CROs can be involved at any or all of these stages. Some focus on early-phase work, running the small, tightly controlled studies that first test a drug in healthy volunteers. Others specialize in the large Phase 3 trials that enroll thousands of patients and generate the evidence regulators use to decide whether a drug is safe and effective enough to approve.
Throughout this process, the CRO acts as a partner to the sponsoring company, not a replacement. The drug developer retains control over the science and the key decisions. The CRO provides the operational machinery: the project managers, the data systems, the site monitors, and the regulatory specialists who turn a study protocol into actual results. When a trial succeeds, the CRO helps compile the data into the formal submission that goes to the FDA, EMA, or other regulatory agencies for review.
For treatments that win approval, CROs sometimes continue their involvement by running post-marketing studies (Phase 4) that track the drug’s safety and effectiveness in the broader population over time.